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ABSTRACT
Background and study aims: the use of endoscopic ultra-
sound-guided biliary drainage (EUS-BD) has increased in 
cases of failed endoscopic retrograde cholangiopancreatog-
raphy (ERCP) and there are some concerns. The main aim of 
the study was to determine the role of EUS-BD in a palliative 
case cohort. The secondary aim was to compare the effica-
cy, safety and survival of EUS-BD and ERCP procedures.
Patients and methods: this was an observational study at 
a single tertiary institution, with a consecutive inclusion 
from January 2015 to December 2016. The inclusion crite-
ria were unresectable tumors of the biliopancreatic region 
with an indication of BD. Statistical comparison analysis 
was performed between the ERCP and EUS-BD groups. The 
incidence between groups was compared using the Chi-
square and Fisher exact tests. The log rank test was used 
to compare the risk of death.
Results: fifty-two cases with an indication of palliative BD 
were included in the study. Transpapillary drainage via 
ERCP was possible in 44 procedures and EUS-BD was re-
quired in eight cases; 15.4% of the cohort and seven using 
lumen apposing metal stent (LAMS). The technical and clin-
ical success of global endoscopic BD was 100% and 88.5% 
(ERCP: 84.6% and 78.9%; EUS-BD: 100% and 62.5%, respec-
tively). Pancreatitis was the most frequent adverse event 
(AE) in the ERCP group (9.62%) and bleeding in the EUS-BD 
(25%). There were fatal AEs in ERCP (1.9%) and EUS-BD 
(25%) cases. Patient survival was higher with ERCP trans-
papillary stents compared to EUS-guided stents, which was 
statistically significant (p = 0.007).
Conclusions: the requirement of EUS-BD in palliative bil-
iopancreatic pathology is not marginal. EUS-BD is associ-
ated with a lower survival rate and a higher rate of fatal AE, 
which argues against its use as a first choice procedure.
Key words: Biliary drainage. Endoscopic ultrasound. En-
doscopic retrograde cholangiopancreatography. Pancreatic 
cancer. Biliopancreatic diseases.
INTRODUCTION
Transpapillary access by endoscopic retrograde cholan-
giopancreatography (ERCP) is the procedure of choice for 
biliary drainage (BD) in patients with unresectable malig-
nant tumors of the biliopancreatic region (1-4). However, 
this procedure is not always successful as 4% to 16% of 
ERCPs fail due to the impossibility of biliary cannulation 
(5-7). In patients with biliopancreatic neoplasias, the main 
reasons for failure are tumor invasion and the inability to 
reach the papilla due to duodenal obstruction. Percutane-
ous transhepatic biliary drainage (PTBD) has been used in 
cases where ERCP fails. However, this technique is associ-
ated with significant morbidity and a lower quality of life 
due to the external drainage. 
In recent years, endoscopic ultrasound-guided biliary drain-
age (EUS-BD) has been increasingly used as an alternative 
when ERCP fails. Recently, a great number of studies re-
lating the experiences of different centers have been pub-
lished. However, the correct strategy for EUS-BD has not 
been clearly established (8). Despite the doubts about its 
efficacy and safety, the increased use of EUS-BD has even 
led to the proposal of this procedure as a first-line treat-
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ment for patients with distal malignant biliary obstruction 
(9). Nevertheless, the optimal proportion of patients with 
malignant biliopancreatic disease in whom ERCP fails and 
EUS-BD is required is unknown. In addition, there are ob-
vious differences from country to country (4). Furthermore, 
the recent innovations in this field such as lumen apposing 
metal stents (LAMS) have helped to expand the role of EUS-
BD as an attractive option to simplify some technical steps. 
However, some serious concerns exist related to the safety 
and real clinical success of this option (10).
The main aim of this study was to determine the role of 
EUS-BD in palliative patients with biliopancreatic tumors, 
which is the most frequent scenario in our setting. The sec-
ondary aims were to compare the efficacy and safety of the 
endoscopy BD approach and the survival of patients with 
ERCP-transpapillary stents vs EUS-guided transmural stents.
MATERIAL AND METHODS
This was an observational cohort study at a single tertia-
ry-care public institution in Barcelona, in an endoscopy unit 
with a high volume of ERCPs (more than 700 per year). 
All patients with biliary obstruction due to unresectable or 
inoperable malignant tumors, with indication of BD, were 
consecutively recruited into the study and data was stored 
in a dedicated database. Exclusion criteria were a benign 
pathology, a previous BD, resectable borderline cancer, se-
vere coagulopathy (protombin time > 1.5), severe throm-
bocytopenia (platelet count < 50 x 109/l) and a lack of data 
or follow-up. The inclusion period was 24 months (from 
January 2015 through December 2016), with a follow-up 
period of at least one year after the procedure. 
The tumors were catalogued as unresectable depending 
upon the presence of metastatic disease and the vascular 
invasion, according to the findings of imaging tests (com-
puted tomography, magnetic resonance imaging or EUS). 
In cases of pancreatic cancer, the consensus of the National 
Comprehensive Cancer Network was followed (11). The pa-
tients were classified as inoperable after the individualized 
evaluation of each case by a multidisciplinary committee, 
according to the general clinical condition of the patient, the 
baseline pathologies and the performance status.
The study was approved by the hospital institutional review 
board and all patients provided written informed consent. 
Furthermore, no financial support or free devices were re-
ceived. 
Procedures
Two expert interventional endoscopists, with an experience 
of more than 100 EUS-guided transmural procedures, per-
formed the procedures. Prophylactic doses of intravenous 
antibiotics were administered before all procedures, which 
were performed with an anesthesiologist who provided 
deep sedation. 
The transpapillary approach by ERCP was the procedure 
of choice in all patients for BD. EUS-DB was considered in 
cases of a failed ERCP that was due to the inability to reach 
the papilla or biliary cannulation failure. In the majority of 
cases, this was performed directly after the failed ERCP in 
the same session, or in a second programmed procedure if 
there was any doubt about the palliative attitude, potential 
resectability or nature of the lesion.
A duodenoscope was used for the ERCP procedures (TJF-
145, TJF-Q180V, Olympus, Europe), using the single-oper-
ator wire-guided cannulation technique with a standard 
papillotome plus short-guidewire (Autotome™; 0.035 inch 
jagwire Boston Sc; 0.025 visiglide). In cases of difficult bil-
iary cannulation due to papilla tumor involvement, a pre-
cut needle-knife (MicroKnife™ XL, triple-lumen, Boston SC) 
or transpancreatic sphicterotomy were considered, which 
was at the discretion of the endoscopist. The transpapillary 
stents were self-expandable metal stents (SEMS) or plastic 
stents in cases of hilar cholangiocarcinoma. The choice of 
the type (uncovered, partially covered, or fully covered) and 
size was at the discretion of the endoscopist. 
A therapeutic linear echoendoscope (GF-UCT140 or GF-
UCT180, Olympus, Europa, or EG-530 UT2, Fujifilm, Tokyo, 
Japan) was used in EUS-BD procedures. The procedure 
chosen for performing the EUS-BD was the direct trans-
mural stenting, using the choledochoduodenostomy (CDS) 
approach as the method of choice and considering the 
hepatogastrostomy (HGS) in case of non-accessible papil-
la. A fully covered LAMS was used in all CDS cases (Hot 
AXIOS™; 6 or 8-mm x 8-mm; Boston Scientific, MA, USA) 
and a HGS case was performed employing a plastic stent. 
An example of an EUS-guided BD using LAMS for a pan-
creatic tumor is shown in figure 1. 
Post-procedure care and follow-up
In accordance with the protocol of our center, there was 
a minimum hospital stay of 24 hours with a blood analy-
sis. On discharge, patients were followed up in outpatient 
clinics between two and four weeks after the procedure, 
in order to assess the clinical success of the procedure. 
Subsequently, patients received oncological or palliative 
treatment according to the criteria of the Oncology Depart-
ment and the Palliative Care Unit. Patients were followed 
up during a period of at least one year after the procedure 
in order to analyze the results of the different endoscopic 
approaches such as stent permeability.
Definitions
Technical success was defined as a successful stent place-
ment at the intended position determined by endoscopy 
and fluoroscopy. Clinical success was defined as a reduc-
tion in bilirubin by 50% at 2-4 weeks after stent placement, 
meaning that the biliary stent was functional. Procedure 
time was defined from the insertion of the endoscope to its 
removal. Procedure safety was considered within the first 
two weeks. Adverse events (AE) were defined and graded 
according to the ASGE lexicon severity grading system (12). 
Statistical analysis
Categorical variables were described using the mean of the 
number of cases and percentages with respect to the total 
by category. Continuous variables were described by the 
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mean of the number of cases, the mean and the standard 
deviation or the median and the interquartile range (IQR).
The incidences of clinical and technical success and AEs 
in the two groups of procedures (ERCP and EUS-BD) were 
compared using the Chi-square test or Fisher’s exact test. 
Time until death was assessed using the Kaplan-Meier es-
timator. The log rank test was used to compare the risk of 
death between the study groups. A retrospective statistical 
analysis was performed. The level of statistical signifi cance 
was set at 0.05 and the R version 3.4.0 for Windows statis-
tical software was used for data analysis.
RESULTS
Role of EUS-BD
A total of 52 patients with unresectable or inoperable ma-
lignant tumors of the biliopancreatic region underwent an 
endoscopic BD during the study period. In all cases, an at-
tempt was made to perform a transpapillary BD via ERCP. 
Figure 2 shows a fl owchart with the results of accessibility 
to the papillary area, the biliary cannulation rates and the 
assignment of patients to each BD modality. EUS-BD was 
required in 15.4% of patients in the cohort due to six cases 
of tumoral papilla and two cases of a non-accessible papil-
la. The CDS approach was performed in 87.5% of cases and 
the HGS in 12.5%.
Technical aspects
Transpapillary biliary cannulation with a sphincterotome and 
guidewire was used in 50% of cases, a needle-knife precut in 
Fig. 1. Example of EUS-guided biliary drainage in an unresectable pancreatic tumor. A. Duodenal 
papilla with tumor invasion signs, in a failed ERCP case. B. Common bile duct access by EUS-
guided puncture. C. Cholangiography with a dilated common bile duct and a malignant distal 
stricture. D. EUS-guided transmural bile duct drainage using a cautery-tipped stent delivery 
system (Hot-AXIOS™). E. EUS image of a lumen-apposing metal stent delivered inside the 
common bile duct. F. The proximal end of a biliary LAMS located at the duodenum.
Fig. 2. Flowchart of all endoscopic biliary procedures.
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(15.9%), partially covered SEMSs (72.7%), uncovered SEMSs 
(2.3%) and plastic stents (9.1%) (WallFlex™, Advanix; Boston 
SC, MA, USA). The details of the EUS-guided transmural 
biliary drainage procedures are presented in the supplemen-
tary table. 
Efficacy and safety of ERCP and EUS-BD
Table 1 summarizes the technical and clinical success, the 
AEs and their degree of severity in the ERCP and EUS-BD 
approach. No statistically significant differences were de-
tected between the groups. Excluding the not-accessible 
papilla cases, the technical and clinical success of the ERCP 
was slightly higher than that reflected in the table (88% and 
82%, respectively). The global technical and clinical success 
of the endoscopic BD (ERCP plus EUS-BD) was 100% and 
88.5%, respectively.
Pancreatitis was the most frequently observed AE in the 
ERCP group (9.62% of cases, 80% mild), whereas bleeding 
(25%) was the most frequent in the EUS-BD group. In the 
ERCP group, most of the AEs were mild (7.7%) and fatal-
ities were unusual (1.9%). In contrast, all AEs observed 
were fatal in the EUS-BD group (25%). However, this differ-
ence was not statistically significant. No intra-procedure 
AEs were reported and all appeared during the post-pro-
cedure period.
Comparative patient survival
In order to assist in the assessment of the equivalence 
of the two groups, table 2 summarizes the demographic 
data and the characteristics of the biliopancreatic tumors 
in ERCP transpapillary stents and EUS-guided stents. No 
significant differences were found with regard to the clin-
ical parameters such as ASA, albumin, bilirubin levels 
or the existence of metastasis. Table 3 summarizes the 
procedure details and the outcomes of the different stent 
approaches. The procedure time was slightly longer in the 
transpapillary group and the functional success was high-
er compared to the EUS-guided transmural stents (93.2% 
vs 62.5%). This difference was statistically significant (p 
= 0.04). 
Patient survival was longer with ERCP transpapillary stents 
compared to EUS transmural stents and this difference 
was statistically significant, with a median survival of 203 
days vs 37 days (p = 0.007). Survival was recalculated af-
ter excluding the cases of fatal AE in order to rule out the 
influence of the AEs on survival. A statistically significant 
longer survival rate was maintained in the group with the 
stents placed via ERCP (median survival of 203 days vs 90 
days, p = 0.047). Figure 3 shows the Kaplan-Meier curves 
of survival, compared with the log rank test.
Table 1. Technical success, clinical success and adverse 






Technical success, n (%) 44 (84.6) 8 (100) 0.582
Clinical success, n (%) 41 (78.9) 5 (62.5) 0.374
Adverse events†, n (%) 8 (15.4) 2 (25.0) 0.610
 Pancreatitis rate, n (%) 5 (9.6) 0 (0) -
 Bleeding rate, n (%) 2 (3.8) 2 (25) -
 Infection rate, n (%) 1 (1.9) 0 (0) -
Severity of adverse events, n (%) 0.128
 Mild 4 (7.7) 0 (0) -
 Moderate 3 (5.8) 0 (0) -
 Fatal 1 (1.9) 2 (25) -
*All cases, including non-accessible papilla. †Adverse events within the first two weeks.
Supplementary Table. Procedure details of the EUS-guided transmural biliary drainage cases








1 M 63 Pancreas Tumoral CDS HXS 06-08 Yes 6
2 F 58 Pancreas Tumoral CDS HXS 06-08 No 56




4 F 80 Pancreas Tumoral CDS HXS 06-08 No 6
5 M 86 Pancreas Tumoral CDS HXS 08-08 + DPT 10 Fr, 5 cm No 18
6 F 62 Pancreas Tumoral CDS HXS 06-08 + DPT 10 Fr, 5 cm No 161
7 F 83 Pancreas Tumoral CDS HXS 06-08 + DPT 10 Fr, 5 cm Yes 1
8 F 70 Pancreas Not accessible HGS Plastic 7 Fr, 9 cm No 124
AE: adverse event; CDS: choledochoduodenostomy; DPT: double-pigtail stent; EUS-BD: endoscopic ultrasound guided biliary drainage; M: male; F: female; HGS: hepatogastrostomy; HXS: Hot-AXIOS™ 
stent; SEMS: self-expandable metal stent.
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Table 2. Comparative demographic data and 
characteristics of the biliopancreatic region tumors, 









Age, mean (SD), years 69.9 (10.8) 73.0 (10.9) 0.482
Sex, n (%) 0.262
 Female 22 (50) 6 (75) -
 Male 22 (50) 2 (25) -
ASA, n (%) 0.249
 I 2 (4.55) 0 (0) -
 II 19 (43.2) 1 (12.5) -
 III 21 (47.7) 7 (87.5) -
 IV 2 (4.55) 0 (0) -
Bilirubin, median (Q1; Q3) mg/dl 12.3 [3.39;21.4] 15.6 [10.6;18.4] 0.577
Albumin, median (Q1; Q3) g/dl 3.3 (2.65; 3.78) 3.15 [2.98;3.37] 0.611
Clinical manifestation, n (%) 0.892
Obstructive jaundice 32 (72.7) 7 (87.5) -
 Acute cholangitis 4 (9.09) 1 (12.5) -
 Cholestasis 5 (11.4) 0 (0) -
 Constitutional syndrome 2 (4.55) 0 (0) -
 Abdominal pain 1 (2.27) 0 (0) -
Tumors, n (%) 0.371
 Pancreas 34 (77.3) 7 (87.5) -
 Cholangiocarcinoma 7 (15.9) 0 (0) -
 Others† 3 (6.8) 1 (12.5) -
Metastatic disease, n (%) 0.458
 Yes 20 (45.5) 5 (62.5) -
 No 24 (54.5) 3 (37.5) -
Unresectable tumors, n (%) 40 (90.9) 8 (100) 1.000
Inoperable patients, n (%) 4 (9.09) 0 (0) 1.000
ASA: American Society of Anesthesiologists physical status classifi cation. *Excluding the failed 
ERCP cases. †Other tumors, including biliopancreatic involvement due to colorectal cancer, 
urothelial/kidney cancer and osteosarcoma. 
Table 3. Procedure details and outcomes of the transpapillary ERCP stents compared with the EUS-guided stents
ERCP transpapillary
stents




Procedure time, mean (SD), minutes 40.4 (12.4) 29.2 (11.0) 0.105
Clinical success, n (%) 41 (93.2) 5 (62.5) 0.040
Number of drainage interventions required, mean (SD) 1.39 (0.92) 1.25 (0.46) 0.533
Number of cases requiring re-intervention, n (%) 9 (20.4) 2 (25) -
Survival, mean (SD), days 250 (224) 67 (71) [0.20; 4.44] < 0.001
Survival, median (Q1; Q3) days 203 (46; 410) 37 (6; 133) [0.20; 4.44] 0.007
Survival, mean (SD), days† 256 (224) 88 (71) [0.20; 4.44] 0.001
Survival, median (Q1; Q3) days† 203 (47; 414) 90 (28; 152) 0.047
*Excluding the failed ERCP cases. †Excluding fatal adverse events.
Fig. 3. A. Kaplan-Meier survival curve of the time until 
death in the two groups, compared with the log rank test. 
B. Kaplan-Meier survival curve of the time until death 
in the two groups, compared with the log rank test and 
excluding fatal adverse events.
A
B
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Palliative BD, which is required in patients with unresect-
able malignant biliopancreatic tumors, is a demanding 
procedure. Transpapillary access via ERCP continues to be 
the procedure of choice. However, despite the development 
of new instruments and devices for performing advanced 
cannulation techniques, the rate of failed ERCP in these 
patients is not negligible (4). In recent years, EUS-BD has 
been proposed as an option to increase the endoscopic BD 
rate when ERCP fails.
Several EUS working groups have considered EUS-BD as 
a priority research topic, in an effort to accelerate its de-
velopment and standardize the procedure (13). In recent 
years, a large number of studies have been reported with 
the aim of establishing the role of EUS-BD in the clinical 
practice and compare the effectiveness and safety of its 
different modalities. Despite the enthusiasm associated 
with this technique, the recently updated guidelines of the 
European Society of Gastrointestinal Endoscopy (ESGE) 
still recommend restricting the use of EUS-BD to cases 
where standard ERCP techniques have failed (strong rec-
ommendation, low quality evidence) (4). Due to this lack 
of available evidence, we feel that the implementation and 
extended use of EUS-BD must be evaluated with caution. 
Furthermore, this must also be supported by strong ev-
idence, in terms of safety and effectiveness, combined 
with an adequate comparison with the alternatives already 
available. 
Holt et al. published their experience with the aim to deter-
mine how often EUS-BD is really needed in a tertiary-level 
care center. The overall ERCP failure rate was 1.7% in 524 
cases of native papilla and there was an EUS-BD indication 
in 0.6% of cases (7). Along the same lines, Tonozuka et al. 
reported the need for EUS-BD in only 3% of a total of 634 
cases from a referral center in Japan (14), while Nakai et al. 
reported a similar rescue EUS-BD rate of 3.1% (15). In our 
unit, the failed biliary cannulation rate was around 2.3% in 
native papilla, similar to reported experiences (16). Accord-
ing to the data reported from referral centers, the need for 
EUS-BD is quite low. Furthermore, serious AEs may occur 
and should therefore not be used as a substitute for a lim-
ited ERCP technique. In addition, the initial aim should be 
the perfection of ERCP skills. 
Unlike the aforementioned series, this present cohort only 
included patients with malignant biliopancreatic obstruc-
tion, meaning a more difficult biliary cannulation due to 
the tumoral papilla or non-accessible duodenum. Thus, the 
need for an EUS-guided technique as a rescue option after 
an ERCP failure was higher (15.4%), which may explain the 
more demanded use of EUS-BD. 
The use of EUS-BD to date in our center has been per-
formed in individualized cases with rigorous selection crite-
ria. Its use in benign pathologies is well-selected with prior 
agreement of a multidisciplinary committee. In malignant 
pathologies, EUS-BD is mainly considered in palliative sce-
narios. However, the general tendency at our center is to 
avoid EUS-BD in patients who may be potential candidates 
for surgical treatment. This is due to the fact that there is 
some controversy regarding how an EUS-guided transmu-
ral BD might alter a potential surgical technique.
The EUS-BD efficacy rates achieved in this study may be 
distant from some other studies. Three meta-analyses re-
ported that EUS-BD had a clinical success rate of 87-94% 
(17-19) and a recent review evaluated the feasibility of 
LAMS in EUS-BD technique, with a clinical success rate 
of 98.9% (10). However, it is important to note that these 
data usually come from retrospective case-series studies. 
The risk of publication bias cannot be excluded and these 
results should be interpreted with caution. In addition, this 
technique is not standardized and there is a wide variability 
of results between centers and a lack of randomized clini-
cal trials to evaluate actual efficacy and safety. The global 
EUS-BD clinical success rate of this study was acceptable. 
Furthermore, in our experience, this procedure has a more 
defined clinical role as a rescue maneuver after a failed 
ERCP in the same session. This is mainly in cases of palli-
ative biliary drainage and in well-selected benign biliopan-
creatic scenarios (16,20).
Kawakubo et al. compared EUS-guided CDS and trans-
papillary BD as first-line procedures in malignant obstruc-
tions in a pilot study, with an equivalent clinical success 
and overall AE rate (9). Post-procedural pancreatitis was 
only observed in the transpapillary group and therefore, 
they concluded that an EUS-guided BD approach would 
be feasible as a first-line treatment. The potential risk of 
AEs associated with EUS-BD is well known and was well 
reflected in recent meta-analyses with reported AE rates of 
17 and 23% (17,18). In our opinion, this means that EUS-BD 
should not be recommended as a first-line procedure and 
its use is restricted to failed ERCP and well-selected cases 
at expert centers. 
In this cohort, there were no statistically significant differ-
ences in the comparison of the overall AE rates. The EUS-
BD AE rate was 25%, which is similar to the results of the 
previously reported meta-analysis. However, the mortality 
rate was higher. This could be explained as an overestimate 
due to the make-up of our cohort, which consisted of pa-
tients with advanced-stage cancers and a poor prognosis. 
Thus, resulting in a limitation of therapeutic efforts in the 
management of AEs by avoiding invasive procedures. 
With regard to the survival results obtained in our study, 
the patients with transpapillary stents via ERCP had a statis-
tically significant longer survival compared to the patients 
with EUS-guided stents. The explanation seems to lie in 
the stent design, as a transpapillar SEMS via ERCP has a 
tubular design that offers more physiological drainage, 
whereas the majority of deployed transmural stents via 
EUS-BD were LAMS, which has a less anatomical design 
and associated risks related to the possibility of occlusion. 
Thus, the question as to whether a double-pigtail stent with-
in the LAMS is recommended to prevent self-occlusion is 
left open (21). 
The appearance of doubts concerning EUS-BD vs PTBD 
may be common in clinical care. A recent meta-analysis 
found that clinical success was similar with the two tech-
niques, although EUS-BD had a lower AE rate (22). In ad-
dition, Khashab et al. observed that EUS-BD had a lower 
need for re-interventions and lower cost compared to PTBD 
(23). However, it should be noted that all these data were 
reported by endoscopists and thus, these comments should 
be interpreted with caution. 
Endoscopic biliary drainage in unresectable biliary obstruction: the role of endoscopic ultrasound-guidance in a cohort study
REV ESP ENFERM DIG 2019:111(9):683-689 
DOI: 10.17235/reed.2019.6225/2019
689
The limitations of this study include a limited number of 
cases, a retrospective analysis (possibility of loss of cases) 
and a lack of knowledge about the role of LAMS in the 
EUS-BD. Questions such as the ideal LAMS size, the role 
of double-pigtail within LAMS and the actual clinical suc-
cess and safety remain unanswered. At the same time, it 
is important to highlight the homogeneity of our cohort, 
the consecutive inclusion and an internal protocol from an 
experienced single center. 
In conclusion, the need for EUS-guided transmural BD in 
palliative malignant biliopancreatic pathology is not negli-
gible. In our opinion, the potential severity and the AE rate 
of EUS-BD suggests that this approach should not be used 
as the initial modality and its role should be restricted to 
cases of ERCP failure in expert centers. However, as with 
any new technique with a great potential, there is a need for 
scientific evidence to establish its actual role in the clinical 
practice and its associated safety. 
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